A framework for assessing risks to children from exposure to environmental agents

Environmental Health Perspectives

Volumn 112, Issue 2, 2004, Pages 238-256

  Daston, George ^a   Faustman, Elaine ^b   Ginsberg, Gary ^c   Fenner Crisp, Penny ^d   Olin, Stephen ^d   Sonawane, Babasaheb ^e   Bruckner, James ^f   Breslin, William ^g  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Strategic Resources Management   (United States)

^d International Life Sciences Institute   (United States)

^e U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

^g ELI LILLY AND COMPANY   (United States)

Author keywords

Children's health; Developmental toxicity; Framework; Life stage; Risk assessment; Toxicodynamics; Toxicokinetics

Indexed keywords

TOXIC SUBSTANCE;

ARTICLE; CHILD; CHILD DEVELOPMENT; CHILD HEALTH; CONCEPTION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL PROTECTION; HUMAN; INFORMATION PROCESSING; ORGANOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT; TOXICOKINETICS; TOXICOLOGY; UNITED STATES;

EID: 1042292061     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.6182     Document Type: Article

References (88)

1. Adams J, Barone S Jr, LaMantia A, Philen R, Rice DC, Spear L, et al. 2000. Workshop to identify critical windows of exposure for children's health: neurobehavioral work group summary. Environ Health Perspect 108:535-544.
2. Adkins B. 2000. Development of neonatal Th1/Th2 function. Int Rev Immunol 19:157-171.
3. Anderson LM, Diwan BA, Fear NT, Roman E. 2000. Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. Environ Health Perspect 108:573-594.
4. Anderson LM, Jones AB, Riggs CW, Kovatch RM. 1989. Modification of transplacental tumorigenesis by 3-methyl-cholanthrene in mice by genotype at the Ah locus and pretreatment with beta-naphthoflavone. Cancer Res 49:1676-1681.
5. Barker N, Hadgraft J, Rutter N. 1987. Skin permeability in the newborn. J Invest Dermatol 88:409-411.
6. Barr M Jr, DeSesso JM, Lau CS, Osmond C, Ozanne SE, Sadler TW, et al. 2000. Workshop to identify critical windows of exposure for children's health: cardiovascular and endocrine work group summary. Environ Health Perspect 108:569-571.
7. Bunn TL, Parsons PJ, Kao E, Dietert RR. 2001a. Gender-based profiles of developmental immunotoxicity to lead in the rat: assessment in juveniles and adults. J Toxicol Environ Health 64:101-118.
8. Bunn TL, Parsons PJ, Kao E, Dietert RR. 2001b. Exposure to lead during critical windows of embryonic development: differential outcome based on stage of exposure and gender. Toxicol Sci 64:57-66.
9. Byczkowski JZ, Kinkead ER, Leahy HF, Randall GM, Fisher JW. 1994. Computer simulation of the lactational transfer of tetrachloroethylene in rats using a physiologically-based model. Toxicol Appl Pharmacol 125:228-236.
10. Chen S, Golemboski KA, Sanders FS, Dietert RR. 1999. Persistent effect of in utero meso-2,3-dimercaptosuccinic acid (DMSA) on immune function and lead-induced immunotoxicity. Toxicology 132:67-79.
11. Clewell HJ, Gearhart JM, Gentry PR, Covington TR, VanLandingham CB, Crump KS, et al. 1999. Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. Risk Anal 19:547-558.
12. Clinton WJ. 1997. Executive Order 13045. Protection of Children from Environmental Health Risks and Safety Risks. Fed Reg 62:19883-19888.
13. Cresteil T. 1998. Onset of xenobiotic metabolism in children: toxicological implications. Food Addit Contam 15:45-51.
14. Dietert RR, Etzel RA, Chen D, Halonen M, Holladay SD, Jarabek AM, et al. 2000. Workshop to identify critical windows of exposure for children's health: immune and respiratory systems work group summary. Environ Health Perspect 108:483-490.
15. Dorne JLCM, Walton K, Renwick AG. 2001. Uncertainty factors for chemical risk assessment: human variability in the pharmacokinetics of CYP1A2 probe substrates. Food Chem Toxicol 39:681-696.
16. Fanucchi MV, Buckpitt AR, Murphy ME, Plopper CG. 1997. Naphthalene cytotoxicity of differentiating Clara cells in neonatal mice. Toxicol Appl Pharmacol 144:96-110.
17. Faustman EM, Lewandowski TA, Hoeft JA, Bartell SM, Wong EY, Griffith WC. 2003. Biomarkers for children's health: developing biologically based risk assessment models for linking exposure and health effects. Inst Risk Anal Risk Commun Publ 3:1-25.
18. Faustman EM, Ponce RA, Seeley MR, Whittaker SG. 1997. Experimental approaches to evaluate mechanisms of developmental toxicity. In: Handbook of Developmental Toxicology (Hood R, ed). New York:CRC Press, 14-41.
19. Faustman EM, Silbernagel SM, Fenske RA, Burbacher TM, Ponce RA. 2000. Mechanisms underlying children's susceptibility to environmental toxicants. Environ Health Perspect 108(suppl 1):13-21.
20. Finette BA, Poseno T, Vacek PM, Albertini RJ. 1997. The effects of maternal cigarette smoke exposure on somatic mutant frequencies at the hprt locus in healthy newborns. Mutat Res 377:115-123.
21. Garland M, Szeto HH, Daniel SS, Tropper PJ, Myers MM, Stark RI. 1998. Placental transfer and fetal metabolism of zidovudine in the baboon. Pediatr Res 44:47-53.
22. Gentry PR, Covington TR, Anderson ME, Clewell HJ III. 2002. Application of a physiologically based pharmacokinetic model for isopropanol in the derivation of a reference dose and reference concentration. Regul Toxicol Pharmacol 36:51-68.
23. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. 1997. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high dose busulfan. Cancer Res 57:5509-5516.
24. Ginsberg G, Slikker W Jr, Buckner J, Sonawane B. 2004. Incorporating children's toxicokinetics into a risk framework. Environ Health Perspect 112:272-283.
25. Ginsberg GL, Hattis D, Sonawane B, Russ A, Banati P, Kozlak M, et al. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci 66:185-200.
26. Haddad S, Restieri C, Krishnan K. 1999. Physiological modeling to characterize adult-children differences in pharmacokinetics. Abstract # 657. Toxicologist 48:140.
27. Hashimoto H, Nakagawa T, Yokoi T, Sawada M, Itoh S, Kamataki T. 1995. Fetus-specific CYP3A7 and adult-specific CYP3A4 expressed in Chinese hamster CHL cells have similar capacity to activate carcinogenic mycotoxins. Cancer Res 55:787-791.
28. Heo Y, Lee WT, Lawrence DA. 1997. In vivo the environmental pollutants lead and mercury induce oligo T cell responses skewed toward type-2 reactivities. Cell Immunol 179:185-195.
29. Hines RN, McCarver DG. 2002. The ontogeny of human drug metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300:355-360.
30. Holladay SD, Smialowicz RJ. 2000. Development of the murine and human immune system: differential effects of immunotoxicants depend on time of exposure. Environ Health Perspect 108:463-473.
31. ILSI RSI. 1996. Research Needs on Age-Related Differences in Susceptibility to Chemical Toxicants. Report prepared by an ILSI RSI working group. Washington, DC:International Life Sciences Institute Risk Science Institute.
32. IOM (Institute of Medicine). 1997. Dietary reference intakes. In: Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC:National Academy Press, 31-35.
33. IOM (Institute of Medicine). 2001. Appendix A: Origin and framework of the development of dietary reference intakes. In: Dietary Reference Intakes: Applications in Dietary Assessment. Washington, DC:National Academy Press, 179-184.
34. Juchau MR. 1980. Drug biotransformation in the placenta. Pharmacol Ther 8:501-524.
35. Kakiuchi Y, Kohda Y, Miyabe M, Momose Y. 1999. Effect of plasma alpha1-acid glycoprotein concentration on the accumulation of lidocaine metabolites during continuous epidural anaesthesia in infants and children. Int J Clin Pharmacol Ther 37:493-498.
36. Kedderis GL. 1997. Extrapolation of in vitro enzyme induction data to humans in vivo. Chem Biol Interact 107:109-121.
37. Kimmel CA. 2001. Improving risk assessment for human developmental defects: the promise of recent advances in developmental biology and genomics. In: Using Mechanistic Data from Developmental and Molecular Biology for Developmental Toxicity Risk Assessment. Continuing Education Course #16. Society of Toxicology 40th Annual Meeting, 25-29 March 2001, San Francisco, California. Toxicologist 60(suppl):3.
38. 1 by P-450 HFLa in human fetal livers. Mutat Res 227:53-58.
39. Kostial K, Kello D, Jugo S, Rabar I, Maljkovic T. 1978. Influence of age on metal metabolism and toxicity. Environ Health Perspect 25:81-86.
40. Krishnan K, Andersen ME. 1998. Physiological pharmacokinetic models in the risk assessment of developmental neurotoxicants. In: Handbook of Developmental Neurotoxicity (Slikker W, Chang L, eds). New York:Academic Press, 709-725.
41. Landrigan PJ, Kimmel CA, Correa A, Eskenazi B. 2004. Children's health and the environment: public health issues and challenges for risk assessment. Environ Health Perspect 112:257-265.
42. Lee JE, Chen S, Golemboski KA, Parsons PJ, Dietert RR. 2001. Developmental windows of differential lead-induced immunotoxicity in chickens. Toxicology 156:161-170.
43. Lemasters GK, Perreault SD, Hales BF, Hatch M, Hirshfield AN, Hughes CL, et al. 2000. Workshop to identify critical windows of exposure for children's health: reproductive health in children and adolescents work group summary. Environ Health Perspect 108:505-509.
44. Lewandowski TA, Hoeft JA, Bartell SM, Wong EY, Griffith WC, Faustman EM. 2002. Biomarkers for child's health: developing biologically based risk assessment models for linking exposure and health effects. Poster presented at International Society of Exposure Analysis (ISEA), International Society for Environmental Epidemiology (ISEE), August 2002, Vancouver, BC, Canada.
45. Martonen TB, Musante CJ, Segal RA, Schroeter JD, Hwang D, Dolovich MA, et al. 2000. Lung models: strengths and weaknesses. Respir Care 45:712-736.
46. + T cell subsets. Toxicol Appl Pharmacol 111:13-23.
47. McCabe MJ Jr, Singh KP, Rainers JJ Jr. 1999. Lead intoxication impairs the generation of a delayed hypersensitivity response. Toxicology 139:255-264.
48. McCarver DG, Hines RN. 2002. The ontogeny of human drug metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J Pharmacol Exp Ther 300: 361-366.
49. McConnell EE. 1992. Comparative responses in carcinogenesis bioassays as a function of age at first exposure. In: Similarities and Differences between Children and Adults: Implications for Risk Assessment (Guzelian PS, Henry CJ, Olin SS, eds). Washington, DC:ILSI Press, 66-78.
50. Miller MS, Jones AB, Park SS, Anderson LM. 1990. The formation of 3-methylcholanthrene-initiated lung tumors correlate with induction of cytochrome P4501A1 by the carcinogen in fetal but not adult mice. Toxicol Appl Pharmacol 104:235-245.
51. Moore JA, Daston GP, Faustman E, Golub MS, Hart WL, Hughes C Jr, et al. 1995. An evaluative process for assessing human reproductive and developmental toxicity of agents. Reprod Toxicol 9:61-95.
52. Murphy SP, Barr SI, Poos MI. 2002. Using the new dietary reference intakes to assess diets: a map to the maze. Nutr Rev 60:267-275.
53. NRC. 1993. Pesticides in the Diets of Infants and Children. Washington, DC:National Research Council.
54. NRC. 2000. Scientific Frontiers in Developmental Toxicology and Risk Assessment. Committee on Developmental Toxicology. Washington, DC:National Research Council.
55. Olin SS, Sonawane BR. 2003. Workshop to develop a framework for assessing risks to children from exposure to environmental agents. Environ Health Perspect 111:1524-1526.
56. Olshan AF, Anderson L, Roman E, Fear N, Wolff M, Whyatt R, et al. 2000. Workshop to identify critical windows of exposure for children's health: cancer work group summary. Environ Health Perspect 108:595-597.
57. Paule MG, Chelonis JJ, Buffalo EA, Blake DJ, Casey PH. 1999a. Operant test battery performance in children: correlation with IQ. Neurotoxicol Teratol 21:223-230.
58. Paule MG, Cranmer JM, Wilkins JD, Stern HP, Hoffman EL. 1988. Quantitation of complex brain function in children: preliminary evaluation using a nonhuman primate behavioral test battery. Neurotoxicology 9:367-378.
59. Paule MG, Meck WH, McMillan DE, McClure GY, Bateson M, Popke EJ, et al. 1999b. Symposium overview the use of timing behaviors in animals and humans to detect drug and/or toxicant effects. Neurotoxicol Teratol 21:491-502.
60. Pelekis M, Gephart LA, Lerman SE. 2001. Physiological-model-based derivation of the adult and child pharmacokinetic intraspecies uncertainty factors for volatile organic compounds. Regul Toxicol Pharmacol 33:12-20.
61. Pinkerton KE, Joad JP. 2000. The mammalian respiratory system and critical windows of exposure for children's health. Environ Health Perspect 108:457-462.
62. Plopper CG, Weir AJ, Nishio SJ, Chang A, Voit M, Philpot RM, et al. 1994. Elevated susceptibility to 4-ipomeanol cytotoxicity in immature Clara cells of neonatal rabbits. J Pharmacol Exp Ther 269:867-880.
63. Pryor JL, Hughes C, Foster W, Hales BF, Robaire B. 2000. Critical windows of exposure for children's health: the reproductive system in animals and humans. Environ Health Perspect 108:491-503.
64. Renwick AG. 1998. Toxicokinetics in infants and children in relation to the ADI and TDI. Food Addit Contam 15(suppl):S17-S35.
65. Renwick AG, Dorne JL, Walton K. 2000. An analysis of the need for an additional uncertainty factor for infants and children. Regul Toxicol Pharmacol 31:286-296.
66. Rice D, Barone S Jr. 2000. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 108:511-533.
67. Rice JM, Rehm S, Donovan PJ, Perantoni AO. 1989. Comparative transplacental carcinogenesis by directly acting and metabolism-dependent alkylating agents in rodents and nonhuman primates. IARC Sci Publ 96:17-34.
68. Rodier PM. 1977. Correlations between prenatally-induced alterations in CNS cell populations and postnatal function. Teratology 16:235-246.
69. Schulze GE, McMillan DE, Bailey JR, Scallet A, Ali SF, Slikker W Jr, et al. 1988. Acute effects of delta-9-tetrahydrocannabinol (THC) in rhesus monkeys as measured by performance in a battery of cognitive function tests. J Pharmacol Exp Ther 245:178-186.
70. Selevan SG, Kimmel CA, Mendola P. 2000. Identifying critical windows of exposure for children's health. Environ Health Perspect 108:451-455.
71. Slikker W Jr, Beck BD, Cory-Slechta DA, Paule MG, Anger WK, et al. 2000. Cognitive tests: interpretation for neurotoxicity. Toxicol Sci 58:222-234.
72. Slikker W, Hill DE, Young JF. 1982. Comparison of the transplacental pharmacokinetics of 17β-estradiol and diethylstilbestrol in the subhuman primate. J Pharmacol Exp Ther 221:173-182.
73. Smiley-Jewell SM, Nishio SJ, Weir AJ, Plopper CG. 1998. Neonatal Clara cell toxicity by 4-ipomeanol alters bronchiolar organization in adult rabbits. Am J Physiol 274(4 pt 1): L485-L498.
74. Suchy FJ, Bucuvalas JC, Novak DA. 1987. Determinants of bile formation during development: ontogeny of hepatic bile acid metabolism and transport. Semin Liver Dis 7:77-84.
75. U.S. EPA. 1992. Dermal Exposure Assessment: Principles and Applications. EPA/600/8-91/011B. Washington, DC:U.S. Environmental Protection Agency. Available: http://epa.gov/osp/spc/cumrisk2.htm [accessed 15 May 2003].
76. U.S. EPA. 1994. Methods for Derivation of Inhalation Reference Concentrations and Application of Inhalation Dosimetry. EPA/600/8-90/066F. Washington, DC:U.S. Environmental Protection Agency.
77. U.S. EPA. 1995a. Policy on Evaluating Health Risks to Children. Washington, DC:Science Policy Council, U.S. Environmental Protection Agency. Available: http://www.epa.gov/osp/spc/memohlth.htm [accessed 2 December 2002].
78. U.S. EPA. 1995b. Policy for Risk Characterization at the U.S. Environmental Protection Agency. Washington, DC:Science Policy Council, U.S. Environmental Protection Agency. Available: http://www.epa.gov/osp/spc/rcpolicy.htm [accessed 2 December 2002].
79. U.S. EPA. 1997. Guidance on Cumulative Risk Assessment. Part 1: Planning and Scoping. Washington, DC:Science Policy Council, U.S. Environmental Protection Agency. Available: http://www.epa.gov/osp/spc/cumrisk2.htm [accessed 18 December 2003].
80. U.S. EPA. 1999. Guidelines for Carcinogen Risk Assessment. Draft, July. NCEA-F-0644. Washington, DC:U.S. Environmental Protection Agency.
81. U.S. EPA. 2000. Child-Specific Exposure Factors Handbook. NCEA-W-0853. 01 Jun 2000. Washington, DC:U.S. Environmental Protection Agency. Available: http://cfpub.epa.gov/ncea/cfm/recordisplay.cfm?deid=17880 [accessed 6 December 2002].
82. U.S. EPA. 2002. The Grouping of a Series of Triazine Pesticides Based on a Common Mechanism of Toxicity. Washington, DC:Office of Pesticide Programs. Available: http://www.epa.gov/oppsrrd1/cumulative/triazines/triazinescommonmech.pdf [accessed 6 December 2002].
83. U.S. EPA Risk Assessment Forum. 1992. Framework for Ecological Risk Assessment. EPA/630/R-92/001. Washington, DC:U.S. Environmental Protection Agency Available: http://cfpub.epa.gov/ncea/raf/rafrprts.cfm [accessed 6 December 2000].
84. U.S. EPA Risk Assessment Forum. 2000. Summary Report of the Technical Workshop on Issues Associated with Considering Developmental Changes in Behavior and Anatomy When Assessing Exposure to Children. EPA/630/R-00/005. Washington, DC:U.S. Environmental Protection Agency. Available: http://www.epa.gov/ncea/raf/workshops.htm [accessed 2 December 2002].
85. Weiss B. 2000. Vulnerability of children and the developing brain to neurotoxic hazards. Environ Health Perspect 108:375-381.
86. Wester RC, Maibach HI, Surinchak J, Bucks DAW. 1985. Predictability of in vitro diffusion systems. Effect of skin types and ages on percutaneous absorption of trichlorban. In: Percutaneous Absorption (Bronaugh RL, Maibach HI, eds). New York:Marcel Dekker, 223-226.
87. Zemlickis D, Klein J, Moselhy G, Koren G. 1994. Cisplatin protein binding in pregnancy and the neonatal period. Med Pediatr Oncol 23:476-479.
88. Zoetis T, Walls I, eds. 2003. Principles and Practices for Direct Dosing of Pre-weaning Mammals in Toxicity Testing and Research. Washington, DC:ILSI Press.